AVIR FY 2025 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$181M

Net Income

-$158M

EPS (Diluted)

$-1.94

Cash Flow

Operating Cash Flow

-$132M

Free Cash Flow

-$132M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$315M

Total Liabilities

$40M

Stockholders' Equity

$275M

Cash & Equivalents

$96M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$83M	+100.0%
Operating Income	-$181M	-$193M	+6.3%
Net Income	-$158M	-$168M	+6.0%